No Long-Term Cognitive Effects Seen for Menopausal Hormone Therapy
No long-term cognitive effects of mHT were seen in the KEEPS Continuation study, about 10 years after completion of randomized treatment
Semaglutide, Liraglutide May Reduce Hospitalization Risk for Alcohol Use Disorder
Semaglutide and liraglutide also linked to reduction in risks for SUD hospitalization, somatic hospitalizations
AHA: Initial Catheter Ablation Beneficial for Ventricular Tachycardia
Initial strategy of catheter ablation leads to lower risk for composite primary end point versus antiarrhythmic drug therapy
Entinostat + Nivolumab Yields Durable Results in Some Pancreatic Cancer Patients
Primary end point not met, but small subset of advanced pancreatic ductal adenocarcinoma patients showed durable responses
AHA: Tirzepatide Beneficial for Heart Failure With Preserved EF, Obesity
Lower risk for composite of death from cardiovascular causes or worsening heart failure seen with tirzepatide versus placebo
AHA: Half of U.S. Adults Are Eligible for Treatment With Semaglutide
More than 39 million U.S. adults qualify for indications other than weight management alone
Optimal Timing of Maternal RSV Vaccine Determined to Be at Least Five Weeks Before...
Maternal vaccination two to three or three to four weeks before delivery linked to lower cord:maternal transfer ratios versus at least five weeks
Worse Outcomes Seen for Seniors With Alzheimer Disease, Dementia, Polypharmacy
Older adults with ADRD and polypharmacy experience more symptoms, have negative health outcomes
Consensus Statement Issued for Low-Dose Oral Minoxidil for Hair Loss
Seventy-six items achieved consensus, including indications for LDOM versus topical minoxidil, dosing for adults and teens, contraindications
Adding Pembrolizumab Ups Survival in Stage III Undifferentiated Sarcoma
Benefit seen for stage III undifferentiated pleomorphic sarcoma or dedifferentiated or pleomorphic liposarcoma of the extremity and limb girdles
